Good morning. And welcome to the Fourth Quarter 2020 Earnings Call for FMC Corporation. This event is being recorded and all participants are in listen-only mode. After today’s prepared remarks, there will be an opportunity to ask questions. I would now like to turn the conference over to Mr. Michael Wherley, Director of Investor Relations for FMC Corporation. Please go ahead.

Thank you, and good morning, everyone. Welcome to FMC Corporation’s fourth quarter earnings call. Joining me today are Mark Douglas, President and Chief Executive Officer; and Andrew Sandifer, Executive Vice President and Chief Financial Officer. Mark will review our fourth quarter and full year performance, and provide our outlook for 2021 and the first quarter. Andrew will provide an overview of select financial items. Following the prepared remarks, we will take questions. Our earnings release and today’s slide presentation are available on our website and the prepared remarks from today’s discussion will be made available after the call. Let me remind you that today’s presentation and discussion will include forward-looking statements that are subject to various risks and uncertainties concerning specific factors, including but not limited to those factors identified in our earnings release and in our filings with the SEC. Information presented represents our best judgment based on today’s understanding. Actual results may vary based upon these risks and uncertainties. Today’s discussion and the supporting materials will include references to adjusted EPS, adjusted EBITDA, adjusted cash from operations, free cash flow, and organic revenue growth, all of which are non-GAAP financial measures. Please note that as used in today’s discussion, earnings means adjusted earnings, and EBITDA means adjusted EBITDA. A reconciliation and definition of these terms, as well as other non-GAAP financial terms to which we may refer during today’s conference call, are provided on our website. With that, I will now turn the call over to Mark.

Thank you, Michael, and good morning, everyone. Let me start by saying the fourth quarter was an unusually difficult one for our company and we are disappointed in our earnings results. We exceeded the midpoint of our guidance on EPS and EBITDA for a long stretch of quarters, principally because of the strength of our portfolio and our geographic balance, combined with strong execution in the face of extreme weather events and significant industry-specific supply chain disruptions. This quarter was an anomaly, and we will be as transparent as always to explain what happened. We experienced significant logistics and supply chain constraints in the U.S., reduced demand in the U.S. on some lower value herbicides, lower demand in Brazil and Argentina following the drought-related delay to the start of the season, and products that were held up in Argentine customs. On the positive side, we saw strong growth in EMEA and once again broad growth in Asia. We had a very strong quarter from a cash flow perspective, which led to full year free cash flow of $544 million, an 80% increase over 2019. We also posted very solid 2020 overall results despite numerous challenges related to the COVID-19 pandemic and $280 million in revenue headwinds from foreign currencies. Our organic revenue growth was 7%, and our 2% EBITDA growth shows how aggressively we managed costs and implemented price increases to offset as much of that FX headwind as possible. The guidance for Q1 reflects our view of the environment in Brazil, as well as continued logistics and supply chain disruptions occurring around the world. We believe these COVID impacts are perhaps as severe as at any point over the last year. In addition, our very strong Q1 2020 makes this quarter year-over-year comparison a particularly difficult one. All of FMC’s manufacturing facilities and distribution warehouses remain operational and fully staffed despite the ongoing pandemic. However, one of our U.S. toll manufacturers was disrupted in Q4 because of COVID-related staffing issues, illustrating just one of the ongoing business risks during the pandemic. We successfully completed the implementation of our new SAP system in November. We now have a single modern system across the entire company for the first time in our history, which is enabling significant efficiencies in our back office processes. Finally, we provided a thorough technology update to investors on November 17th, highlighting the increasingly positive impact new synthetic and biological active ingredients will have on our business over the next decade, and the ways in which we are driving to be the leader in crop protection innovation. We plan to launch seven new active ingredients and four new biologicals this decade, which we expect will contribute a combined $1.8 billion to $2.1 billion in incremental sales by 2030. We recently announced a new collaboration with Novozymes, a world leader in enzyme discovery and production to research, co-develop, and commercialize biological enzyme-based crop solutions for growers around the world. This adds to research collaborations and partnerships signed in 2020 with Zymergen and Cyclica, and continues our trend of investing in new and innovative technologies that will enhance our long-term competitiveness. Turning to our Q4 results on slide three. We reported $1.15 billion in fourth quarter revenue, which reflects a 4% decrease on a reported basis and a 2% organic growth. Despite those headwinds, we posted double-digit sales growth in Asia, led by India, China, Japan, and Australia, and in the EMEA with double-digit growth across a broad set of countries. Adjusted EBITDA was $290 million, a decrease of 9% compared to the prior year period. EBITDA margins were 25.2%, a decrease of 150 basis points compared to the prior year. Adjusted earnings were $1.42 per diluted share in the quarter, a decrease of 19% versus Q4 2019. This year-over-year decline was primarily driven by the decrease in EBITDA, an increase in tax rate compared to the very low tax rate in Q4 2019, and slightly higher depreciation and amortization, partially offset by lower interest expense and lower non-controlling interest. Moving now to slide four. Q4 revenue decreased by 4% versus the prior year, driven by a 5% FX headwind and a 3% volume decrease. Price increases contributed a positive 4% impact and offset 80% of the FX headwind, delivering a positive 2% organic growth. Volume growth in EMEA and Asia was more than offset by weakness in North America and Latin America. Sales in EMEA increased 45% year-over-year and 42% organically. We saw particularly strong demand for Rynaxypyr insect control applications for specialty crops, as well as herbicides for cereals, especially in France, Spain, Russia, and Germany. We also experienced significant growth in the U.K. as customers secured orders in advance of Brexit. In Asia, revenue increased 11% year-over-year, driven by broad volume growth in India, China, Japan, and Australia. India saw strong demand for rice and pulses in the south, and in sugarcane in the north, in addition to the growth from our recent market access expansion activities. Last earnings call, we highlighted India as a key pillar of growth in Asia, and the strength we saw in Q4 exemplifies this potential, with India growing over 25% organically in the quarter. China saw robust demand for diamide insecticides and fungicides on fruit and vegetables. Growth in Australia was driven by demand for herbicides for cereals and oilseeds, while Japan’s strength came from a variety of insecticides. Turning now to Latin America. Sales decreased 9% year-over-year, but grew 4% excluding significant FX headwinds. Pricing actions across the region offset about 50% of the currency headwind at the earnings level in Q4, substantially more than in the prior two quarters. The Brazil season was delayed by at least 30 days due to hot dry weather, which meant many crops missed applications that will not return. The drought persisted throughout Q4, resulting in lower than expected yields across many crops and it also impacted Argentina and other countries in the region. For Latin America overall, we estimated the drought reduced sales by about $30 million. In Argentina, we also had about $10 million of products held in bonded warehouses that were not released by customs officials in a timely manner. Although these factors reduced Q4 growth in Argentina, 2020 was still our best year ever for the country. In North America, sales decreased 34% year-over-year. Roughly $40 million of this decline was due to supply chain disruptions, including COVID-related factors associated with logistics and a toll manufacturing partner, impacting our ability to meet demand late in December. An additional $30 million of the decrease was due to reduced volume and some lower value pre-emergent herbicides. Our newer herbicides such as Authority Edge, Authority Supreme, and Anthem MAXX continue to add value and grow well. Our biologicals business had a very strong Q4, with sales up in all regions by at least a high-teens percentage, including very strong sales of Quartzo in Brazil and successful launches of Accudo in EMEA and At-Plant and MSDS in South Korea. Turning now to the fourth quarter EBITDA bridge on slide five. We had a $50 million contribution from higher pricing, which was nearly double what we realized in Q3. We also aggressively managed costs to offset nearly all the $30 million year-over-year headwind we had anticipated. However, the FX headwinds were more severe than expected, and the slight volume misses in North America and Latin America were too large to overcome. Moving to slide six for a view of our full year results. We reported $4.64 billion in revenue, which reflects a 1% increase on a reported basis and a 7% organic growth rate. Adjusted EBITDA was $1.25 billion, an increase of 2% compared to 2019, even with nearly $270 million in headwinds from FX. EBITDA margins were 26.9%, an increase of 40 basis points compared to the prior year. 2020 adjusted earnings were $6.19 per diluted share, an increase of 2% versus 2019. This increase was driven by the increase in EBITDA, as well as lower interest expense and a lower share count, offset partially by a higher tax rate compared to the very low tax rates in the prior year and higher depreciation and amortization. Turning to slide seven for some of the drivers behind the full year revenue growth. Overall, volume contributed 4% to revenue growth, while price increases contributed 3%. About $50 million of the 2020 revenue growth came from product launches within the year. In Asia, sales increased 6% year-over-year and 9% organically. Market expansion and share gains in India, coupled with a very strong market rebound in Australia, were the primary drivers. Our diamides were in high demand throughout the region in 2020, as we continued to grow in specialty crops such as rice and fruits and vegetables. Sales in EMEA grew 4% versus 2019 and 6% organically. Demand was driven by diamides on specialty crops, Battle Delta herbicide on cereals, and Spotlight Plus herbicide on potatoes. Latin America posted a 1% year-over-year revenue growth, but high single-digit volume growth and solid price increases led to 17% organic growth. Brazil had robust demand for our products for soybeans and sugarcane, while there was reduced demand acreage for cotton. North America sales decreased 8%, as we had channel destocking in the first half and then a tough Q4 as described earlier. Of note, the Lucento fungicide launch had a strong second year and Elevest insect control had a good launch year. Moving to slide eight, where you can see our full year EBITDA bridge. Volume contributed 9% to the growth, while a combination of stringent cost controls and price increases offset 70% of the impact of foreign currencies. Turning to slide nine and a look at the overall market conditions for 2021. We expect the global crop protection market will be up low-single digits on a U.S. dollar basis. Commodity prices for many of the major crops are higher and stock-to-use ratios have improved compared to this time last year. All regions are seeing some benefit from better crop commodity prices, while the impacts from COVID on crop demand appear to be lessening. Growth in Asia is expected to be in the low to mid-single digits, driven by India, Australia, and ASEAN. Favorable weather should contribute in many countries. The weather-related recovery in Australia is expected to continue. The other three regions are each projected to grow in the low-single digits. Growth in the Latin America market will be strengthened by price recovery from FX headwinds from 2020 in Brazil, continued strength in the soybean market, and an increase of fruit and vegetable exports from Mexico, as well as more normal weather patterns that are forecasted across the region. In the EMEA market, we are seeing a solid market for cereals and specialty crops, which should be helped by improved weather in several parts of the region. The market in North America is projected to have a firm foundation from crop commodity prices, but we are seeing a trend of distributors and retailers looking to strategically reduce their own inventory levels. The specialty crop market is stable, but a more significant change in demand will depend on the pace of the economic recovery. Taking all the above into consideration, we view 2021 as a more positive agricultural macro environment than we did this time last year. Having said that, we are all too well aware of the potential disruptions that COVID and weather could cause in any one quarter. Turning to slide 10 and the review of FMC’s full year 2021 and Q1 earnings outlook. FMC full year 2020 earnings are now expected to be in the range of $6.65 per diluted share to $7.35 per diluted share, a year-over-year increase of 13% at the midpoint. Consistent with past practice, we do not factor in any benefit from planned share repurchases in our EPS estimates. 2021 revenue is forecasted to be in the range of $4.9 billion to $5.1 billion, an increase of 8% at the midpoint versus 2020 and 9% organic growth. We believe the strength of our portfolio will allow us to deliver this organic growth, continuing the multi-year trend of above-market performance. EBITDA is expected to be in the range of $1.32 billion to $1.42 billion, which represents a 10% year-over-year growth at the midpoint. Guidance for Q1 implies year-over-year sales contraction of 7% at the midpoint on a reported basis and 5% organically. We are forecasting an EBITDA decline of 15% at the midpoint versus Q1 2020, and EPS is forecast to be down 18% year-over-year. Turning to slide 11 and full year EBITDA and revenue drivers. Revenue is expected to benefit from 7% volume growth, with the largest growth in Asia and a 2% contribution from higher prices. FX is forecasted to be a 1% top-line headwind. We are expecting broad growth across all regions. Asia has the best overall fundamentals, but we are also seeing the benefit of better weather in Europe, a strong soybean outlook for both Latin America and North America, and a cotton recovery in Brazil next fall. Because of these factors, we are expecting a very strong second half of 2021 relative to the first half. New products such as Overwatch herbicide in Australia based on our Isoflex active and Xyway fungicide in the U.S. are expected to make meaningful contributions. In addition, we are launching Fluindapyr fungicide in the U.S. for non-crop applications. We are forecasting a strong year for each of our product areas. In addition to the continuing strength of Rynaxypyr and Cyazypyr insect controls, insecticide growth is also expected to come from products such as Talisman, Hero, and Avatar. Herbicides should see growth in several of our top brands including Authority, Gamit, Riyata, and Spotlight Plus in addition to the Overwatch launch. Growth in fungicides is forecasted to be driven primarily by the Xyway launch in the U.S. Our EBITDA guidance reflects strong volume and pricing benefits, offset partially by increases in R&D spending, as well as the reversal of some of the temporary cost savings from 2020. We are forecasting a $14 million increase in R&D to bring us to a level of funding that keeps all projects on a critical path to commercialization. Additionally, we are making growth investments in our pharma intelligence, and other precision ag initiatives, new product launches like Overwatch, as well as FMC Ventures. We are also expecting some supply chain cost increases, including logistics and pockets of raw materials. These headwinds will be partially offset by the realization of the final $15 million of SAP synergies, which will give us cumulative SAP synergies of approximately $65 million. Moving to slide 12, where you see the Q1 drivers. On the revenue line, volume is expected to drive a 6% decline, while a 1% contribution from higher prices largely offsets the FX headwind. We expect the benefit of approximately $25 million in sales from Q4 supply and logistics delays to be captured in Q1. This is about half of the Q4 impact. In the U.S., this mistiming limits what we can recoup, and in Argentina, ongoing customs delays in releasing products could cause misapplication windows. There are several headwinds in Q1 revenue that more than offset the flow through from Q4. First, we are facing a particularly difficult comparison in Latin America, where sales increased 26% year-over-year and 38% organically in Q1 2020. Brazil’s cotton business was very strong for us a year ago, and this will not be repeated this season as cotton acreage is down 15%. In EMEA, we are facing continued headwinds from discontinued registrations and the $15 million in Q4 sales related to Brexit that would normally have been sold in the first quarter. Regarding EBITDA drivers, reduced volume is the biggest factor, while pricing is forecast to offset the FX headwind. Costs are expected to be higher by $12 million, driven primarily by the increased R&D investments we mentioned earlier. With that, I will now turn the call over to Andrew.

Thanks, Mark. Let me start this morning with a few highlights from the income statement. FX was a 5% headwind to revenue in the quarter, as expected, with the impact of higher than anticipated local currency-denominated sales in Brazil offset in part by a modest tailwind in the Eurozone. For full year 2020, FX was a 6% headwind to revenue. The Brazilian real represented the vast majority of the FX headwinds in 2020, followed by the Indian rupee, Pakistani rupee, and a broad number of non-euro currencies in EMEA. Pricing actions offset slightly half of the currency headwinds in the year. Looking ahead to 2021, we expect a more stable FX environment, with only a slight headwind to revenues. We will continue to take pricing actions in Brazil to recover the FX impacts from 2020. Overall pricing will be somewhat dampened by price volume choices being made in our Asia business to drive higher growth. Interest expense for the fourth quarter was $34.2 million, down $8.7 million from the prior year period, benefiting from lower debt balances and lower LIBOR rates. Interest expense for full year 2020 was down $7.3 million from the prior year, with the benefit of lower interest rates, partially offset by changes in debt outstanding. Our effective tax rate on adjusted earnings for 2020 was 13.7%, well within our expectations and up from the very low 2019 rate, due to shifts in the geographic mix of taxable earnings and interrelated impacts on the U.S. minimum tax from foreign earnings. The tax rate in the fourth quarter was 14.4% to true up with the full year actual rate. Tax was a headwind to earnings in the quarter due to the very low tax rate in the prior year period. We expect our effective tax rate to be in the range of 12.5% to 14.5% in 2021, similar to 2020. Moving next to the balance sheet and liquidity. Gross debt at year-end was $3.3 billion, essentially flat with the prior quarter, with nearly $600 million of cash on hand. We chose to hold cash on the balance sheet in advance of the seasonal working capital build we see in the first quarter to avoid having to take on as much commercial paper in the beginning of the New Year. As such, gross debt to trailing 12-month EBITDA was 2.6 times at the end of the year, while net debt-to-EBITDA was 2.3 times. We are comfortable in the right leverage range given the excess cash at year-end. We do not expect to carry this level of cash on a steady state basis going forward, so you should expect cash balances to decline through the coming year. Moving to slide 13 and a look at 2020 cash flow and the outlook for 2021. Free cash flow for 2020 was $544 million, with free cash flow conversion from adjusted earnings of 67%, both metrics up 80% from the prior year period. Adjusted cash from operations increased by about $170 million in 2020, with growth in working capital more than offset by lower non-working capital factors and increased EBITDA. Capital additions were down $60 million due to project delays and deferrals related to the COVID-19 pandemic. Legacy and transformation spending was down $14 million due to relatively stable legacy spending, and transformation spending was lower as we completed our SAP implementation. We anticipate full year 2021 free cash flow to be in the range of $530 million to $620 million, an increase of 6% at the midpoint, with free cash flow conversion of 63% at the midpoint. Growth in adjusted cash from operations, and reduced legacy and transformation spending are expected to be partially offset by a significant year-over-year increase in capital additions, as we catch up on projects that were delayed or deferred in 2020 due to the pandemic. Turning to slide 14. We are pleased with our strong free cash flow growth and improvement in free cash conversion. There are a number of moving parts in our 2020 cash flow results and 2020 outlook that merit some further discussion and we will help better explain this trajectory. 2020 free cash flow benefited from a planned real estate assets sale that will not repeat, as well as the unforecasted delay of a lump sum environmental liability payment we expected to be paid in December. Excluding these impacts, 2021 cash flow would have been about $500 million and cash conversion about 62%. Similarly, 2021 free cash flow is negatively impacted by the timing shift of the environmental liability payment. Adjusting for this timing shift, 2021 free cash flow would be about $600 million and cash conversion of 65%. So, on a more comparable basis, free cash conversion steps up from 38% in 2019 to 62% in 2020 and 65% in 2021, getting closer to our 70% to 80% target range for 2023. I note that in this view of cash flow, we have not made any adjustments for the abnormally low capital additions in 2020 or the catch-up to a more normal level in 2021. But this shift is a large part of the reason why cash conversion steps up more slowly in 2021, as the increase in capital additions largely offset the step down in transformation cash spending from the completion of the SAP program. You should expect the capital additions continue in a similar range to 2021 for the next several years to support our organic growth, including new capacity to support new active ingredient introductions. Equally as important as growing our free cash flow is the discipline with which we deploy it. As you can see on slide 15, we continue our balanced approach to cash deployment. We are fully funding our organic growth and making modest inorganic investments to enhance our growth. We are then returning the excess cash to shareholders through dividends and share repurchases, while keeping debt at our targeted leverage levels. In 2020, we deployed nearly $350 million of cash flow while maintaining excess liquidity throughout the pandemic. We deployed $65 million to acquire the remaining rights to the fungicide Fluindapyr. We paid nearly $230 million in dividends, and we repurchased $50 million in FMC shares in the fourth quarter. In 2021, we expect to accelerate cash deployment. We are planning to repurchase between $400 million and $500 million worth of FMC shares in the year, with purchases in every quarter that are more heavily weighted to the second half. We expect to pay dividends approaching $250 million, and we will continue to look for attractive opportunities to make additional modest inorganic investments to complement our organic growth and expand our technological capabilities. I’d like to close with a final update on our SAP S/4HANA ERP system implementation. We had a successful last Go-Live in November and are now operating on a single thoroughly modern system across the entire company for the first time in our history. The Go-Live went better than expected, and we have smoothly transitioned to operating the company and closing the books in the new system. Our new SAP system has enabled significant efficiencies in our back office processes. We captured over $50 million in synergies in 2020, having moved aggressively to accelerate $30 billion in planned savings from 2021 to 2020. We now expect to deliver $15 million in SAP-enabled synergies in 2021, the benefit of which is reflected in our full year guidance for a total of $65 million in synergies from implementing the new system. There will certainly be additional efficiency gains in 2022 and beyond, as we further leverage this generational investment in our business process infrastructure. But we will drive them as part of our business as usual efforts to gain leverage on back office costs as we continue to grow the company. And with that, I will turn the call back over to Mark.

Thank you, Andrew. We had a number of issues in late Q4 that we are having to address. We do not expect all of them to be resolved in Q1. We do, however, see these issues as transitory and are focused on ensuring we can mitigate supply chain risks and continue to expand our market growth opportunities. As you can see from our robust 2021 guidance, we are confident that 2021 will be another year of strong revenue and earnings growth for FMC. We continue to renew our portfolio, launching two new important products in Q1. We continue to invest in our R&D pipeline, and we remain fully committed to bringing new sustainable technologies to our customers. Our overall agenda on sustainability continues to advance with the recent appointment of our first Chief Sustainability Officer and through new partnerships, like the one recently announced with Novozymes. We plan to return about $700 million to shareholders this year through dividends and buybacks. Finally, with our 2021 growth rates above the long-range plan, we remain firmly on track to deliver our five-year plan commitments. Before I close, I’d like to highlight the press release issued yesterday regarding Pierre Brondeau’s retirement as Executive Chairman effective April 27. I very much appreciate his leadership and look forward to his continued involvement as Non-Executive Chairman. I will now turn the call back over to the operator for questions.

Thank you. And the first question will be from Chris Parkinson with Credit Suisse. Please go ahead.

Thank you. To start, many of us have interpreted your guidance as a fairly cautious outlook for the first quarter. You are maintaining your organic revenue growth despite some challenges. Can you share a couple of highlights regarding growth this year? It seems like you are primarily focused on the first half and are still cautiously optimistic about certain regions in emerging Europe. Any insights would help us understand the contrast between the weaker than expected first quarter and what should still be considered a strong year. Thank you.

Yeah. Thanks, Chris. It’s fairly obvious when you look at the release that we have a weak Q1, yet a very strong full year. From our perspective, when we look at what is going on in Q1, it bears some relationships to what is happening in the second half of the year. I will give you some color on that. First of all, when we talk about some headwinds in the quarter, we have headwinds from loss of registrations in Europe. About 50% of the total revenue lost in the whole year occurs in Q1 in Europe. That’s due to the types of products sold in Q1 and the timing. The second aspect involves Latin America. We highlighted that we had a very strong cotton business last year, and this year it is lower due to reduced acreage. We do have some lingering effects from the drought and missed opportunities. We are managing inventories in Brazil carefully. There is no way you go through a fourth quarter with a 30-day delay without impacting performance. Our inventories are elevated, but we are making a decision in Q1 to sell out of inventory and strengthen our market position for the future season. We do see growth in Asia weighed towards the second half of the year, especially in India with promising developments in our herbicide portfolio. We expect continued robust growth in the ASEAN region and good momentum in China as well. Lastly, while we have challenges, we believe the second half of the year will see much stronger performance based on our strategies and growth initiatives.

No. That’s very fair. As always, thank you for the color, Mark.

Thank you. And the next question will be from Adam Samuelson with Goldman Sachs. Please go ahead.

Hi. Thanks. Good morning. Maybe following up on some of the color, Mark, you just gave in response to Chris. Just thinking about how the fourth quarter played out. You came short of where the initial guide had been by about $55 million on EBITDA. And I just want to clarify that the expectation is, given the timing, you don’t necessarily get most of that back in 2021? And could you elaborate on the dilution to distributors reducing inventory in North America?

Yeah. Thanks, Adam. We are working through supply chain issues and getting back some of that in Q1. The reality is we did lose some sales, and we consider that transitory. We don’t expect that to happen in Q4 next year. The commercial team will work hard to recoup this position. The distributors in the U.S. have been focusing on their working capital, which is vital since growers experienced lower income. Therefore, we highlight this trend as it may impact our industry dynamics despite strong commodity prices.

Okay. That's really helpful. If I could just sneak in a quick follow up. As we think about pricing over the course of the year, there’s some carryover pricing from actions in Brazil and South America that you took in the second half. But it seems like the pricing side of things is going to be more back half weighted, is that correct?

Yes, in the second half, particularly when we hit Q3 in Latin America, there will be stronger recovery on pricing, which is typical due to seasonal patterns. We expect to recover pricing and take advantage of better market access in the region. We have about a third of the pricing planned in the first half, but the bulk will be in Q3 and Q4.

That's really helpful. I will pass it on. Thank you.

Thank you.

The next question will come from Stephen Byrne with Bank of America Securities. Please go ahead.

Yes. Good morning. Mark, your 2021 outlook shows low-single digits increases in most regions while your own organic revenue growth is near double-digit, high single-digit. Can you share how those estimates changed in the last six months? How do you think these increased crop prices affect your market growth?

Thanks, Steve. Our outlook has become more optimistic over the last year. We've maintained a resilient approach to market conditions. Strong commodity prices encourage growers to invest in crop protection, aiming for the highest yields and most value. We believe the combination of price recovery and maximizing yield will drive market improvements.

Thank you.

The next question is from Vincent Andrews with Morgan Stanley. Please go ahead.

Hi. This is Steve Haynes on for Vincent. I just wanted to ask about the COVID-related costs that are coming back. Can you quantify how much is coming back and maybe what the risks might be in either direction to that number?

We are seeing roughly about $25 million to $30 million in increased costs related to COGS increases. Furthermore, logistics costs are higher than they have been at any time, with shipping rates rising significantly. Additionally, raw material costs out of China are beginning to increase due to supply constraints.

Our next question will come from Mark Connelly with Stephens. Please go ahead.

Mark, could you give us an update on your diamide licensing and partnership projects? Also, what are your capacity expansion plans and how did your diamide portfolio perform in 2020?

Our diamide partnerships are continuing to grow, from 40 to 50 agreements, emphasizing our collaborative efforts. The revenue from diamides grew significantly; we closed out the year with around $1.8 billion. We acquired over 70 new registrations for our products in 2020, enabling more access to new geographies and crops.

And the next question will be from Laurent Favre with Exane BNPP. Please go ahead.

Thank you. Good morning, all. Mark, I have a question on the phase-outs. Historically, you’ve talked about a 1% to 2% impact for a full year. Will 2021 be much larger than that? Can you talk about the product categories involved?

We're forecasting about a 2% headwind due to registration losses. This year it's roughly split between Europe and Latin America. It involves a mix of older insecticides and fungicides/herbicides, but nothing major that would significantly impact our overall performance.

Okay. So it’s almost 4% for Q1 then?

Yes, it’s much higher in Q1 due to seasonal factors and the significant portion of European impacts occurring during this quarter.

The next question will come from Joel Jackson with BMO Capital Markets. Please go ahead.

Hi. Good morning, everyone. Mark, could you elaborate on the missed opportunity to cotton in Brazil? Is that solely due to acreage shifts, or were there other lost business or share opportunities?

The reduction in cotton is primarily due to a 15% acreage decrease. The missed opportunities refer more to earlier crops affected by the drought where applications may have been missed. Our overall strategy is to maximize the potential across all product offerings in the region to overcome these issues. Regarding generics pressure in North America, we're seeing an increase, especially at the low end of our pre-emergent business. Our strategy has shifted focus on high-end products as the market demands more effective solutions for weed resistance.

Thank you. The next question will come from Michael Sison with Wells Fargo. Please go ahead.

Hey, guys. Good morning. Mark, you outlined the adjusted EBITDA bridge for 2021. Can you provide more insight on how much of that $180 million growth is within your control, such as new products or the diamide portfolio, and how much is at risk?

When we forecast forward, we focus on normal conditions, including weather and pest pressures. We are optimistic about volume and price recovery, particularly as growers are in better financial positions and highly motivated to protect their yields.

And thank you. The last question will come from Kevin McCarthy with Vertical Research Partners. Please go ahead.

Good morning, everyone. Mark, could you elaborate on the Brexit-related boost to sales in EMEA in the fourth quarter? And also on the tolling issue you cited in North America?

Brexit led to a strong demand in the U.K., with a revenue swing of about $15 million to $20 million between Q4 and Q1. We made preemptive plans with our customers which ultimately proved beneficial. On the toll manufacturing front, a specific partner faced COVID-related staff shortages, impacting our outputs for Q4. We are adjusting our network to prevent recurrence and avoid mismatched inventory.

That is all the time that we have for the call today. Thank you, and have a good day.

Ladies and gentlemen, this concludes the FMC Corporation conference call. We thank you for attending. You may now disconnect.